10-Q: Traws Pharma Reports Second Quarter 2024 Results Following Merger, Faces Going Concern Uncertainty

Traws Pharma reports a significant net loss for the second quarter of 2024, driven by a large in-process R&D expense related to the acquisition of Trawsfynydd Therapeutics, and expresses substantial doubt about its ability to continue as a going concern.

Summary

• Traws Pharma, formerly Onconova Therapeutics, reported a net loss of $128.1 million for the six months ended June 30, 2024, compared to a $10.0 million loss in the same period of 2023.
• The significant increase in net loss is primarily due to a $117.5 million non-cash expense for acquired in-process research and development (IPR&D) related to the acquisition of Trawsfynydd Therapeutics.
• The company's cash and cash equivalents stood at $16.9 million as of June 30, 2024.
• Traws Pharma believes its current cash will only fund operations into the fourth quarter of 2024, raising substantial doubt about its ability to continue as a going concern for the next 12 months.
• The company is exploring various funding options, including equity financing and strategic alliances, to address its liquidity concerns.
• The company's revenue remained consistent at $113,000 for both the six-month periods of 2024 and 2023, stemming from a collaboration agreement with SymBio.
• Research and development expenses decreased slightly to $5.9 million for the six months ended June 30, 2024, compared to $6.5 million in the same period of 2023.
• General and administrative expenses increased to $5.3 million for the six months ended June 30, 2024, from $4.3 million in the same period of 2023.
• The company completed the acquisition of Trawsfynydd Therapeutics on April 1, 2024, which included the issuance of common and preferred stock and the assumption of stock options.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with a significant net loss, going concern uncertainty, and potential delisting from Nasdaq. While there are some positive aspects like the merger and pipeline expansion, the overall sentiment is negative due to the company's financial instability.

Positives

• Traws Pharma successfully completed the acquisition of Trawsfynydd Therapeutics, expanding its pipeline with promising virology programs.
• The company raised $14 million through a private placement, providing some capital for ongoing operations.
• Traws Pharma is actively advancing four clinical programs, demonstrating a commitment to drug development.
• The company has initiated a Phase 1 clinical trial for TRX-01 in Australia.
• The company has initiated a Phase 1 clinical trial for TRX-100 in Australia.

Negatives

• Traws Pharma reported a significant net loss of $128.1 million for the first half of 2024.
• The company has expressed substantial doubt about its ability to continue as a going concern.
• The company's cash reserves are projected to be insufficient to fund operations beyond the fourth quarter of 2024.
• The company incurred a large non-cash expense of $117.5 million related to acquired in-process R&D.
• The company restructured its operations, terminating a significant portion of its workforce.
• The company is not in compliance with Nasdaq's minimum bid price requirement and may face delisting.

Risks

• The company's ability to continue as a going concern is uncertain due to insufficient cash reserves.
• The company may not be able to secure additional funding on acceptable terms.
• The company faces risks associated with the integration of Trawsfynydd Therapeutics.
• The company's clinical trials may not be successful, and regulatory approvals may not be obtained.
• The company may not be able to commercialize its product candidates successfully.
• The company is subject to risks related to intellectual property protection and competition.
• The company is not in compliance with Nasdaq's minimum bid price requirement and may face delisting.
• The company may be required to redeem Series C Preferred Stock for cash if shareholder approval for conversion is not obtained, which could significantly deplete cash reserves.

Future Outlook

Traws Pharma anticipates continued operating losses due to research and development costs. The company plans to explore various funding options to support its clinical trials and operations. The company's future success depends on its ability to obtain additional funding and achieve regulatory approvals for its product candidates.

Management Comments

• Management has concluded that substantial doubt exists with respect to Traws Pharma's ability to continue as a going concern within one year after the date that these financial statements are issued.
• Management plans to explore various dilutive and non-dilutive sources of funding, including equity financings, strategic alliances, business development and other sources.
• Management believes that its cash and cash equivalents will be sufficient to fund its ongoing trials and operations into the fourth quarter of 2024.

Industry Context

The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and regulatory hurdles. Traws Pharma's challenges in securing funding and achieving profitability are common in this sector, particularly for clinical-stage companies. The company's focus on both oncology and virology programs diversifies its risk but also increases its operational complexity.

Comparison to Industry Standards

• Traws Pharma's significant net loss and going concern uncertainty are not uncommon for clinical-stage biopharmaceutical companies, especially those undergoing major strategic shifts like a merger.
• Comparable companies in the clinical-stage biopharma space often rely on a combination of equity financing, strategic partnerships, and licensing agreements to fund their operations.
• The $117.5 million in-process R&D expense is a significant one-time charge related to the acquisition, which is typical in such transactions, but it highlights the company's reliance on external acquisitions for pipeline growth.
• The company's cash runway extending only into the fourth quarter of 2024 is a critical concern, as many similar companies aim for at least 12-18 months of cash on hand to ensure operational continuity.
• The company's restructuring efforts, while necessary for cost control, are also a common strategy for companies facing financial constraints in the biopharma sector.
• The company's ongoing clinical trials for TRX-01, TRX-100, Narazaciclib, and Rigosertib are consistent with the development activities of other companies in the same space, but the success of these trials is critical for the company's future.

Management Changes

Corporate Governance

Legal Proceedings

• Steven M. Fruchtman resigned from his positions and claims his resignation was for 'good reason' under his employment agreement, seeking severance compensation, which the company disputes.

Related Party Transactions

• Traws Pharma made payments of $5,024,000 to ChemDiv, Inc., a related party where Dr. Nikolay Savchuk, COO of the Company, is a stockholder and board member.

Stakeholder Impact

• Shareholders face significant dilution due to the issuance of new shares in the merger and private placement.
• Employees experienced a reduction in workforce, with 11 of 17 employees terminated.
• Creditors face increased risk due to the company's going concern uncertainty.
• Customers and partners may be concerned about the company's financial stability and ability to deliver on its commitments.
• Suppliers may face increased risk of non-payment due to the company's financial challenges.

Next Steps

• Traws Pharma will hold a stockholders meeting to approve the conversion of Series C Preferred Stock into common stock.
• The company will continue to advance its clinical programs for TRX100, TRX01, Narazaciclib, and Rigosertib.
• The company will explore various funding options to address its liquidity concerns.
• The company will seek to regain compliance with Nasdaq's minimum bid price requirement.

Key Dates

Keywords

Traws Pharma, Trawsfynydd Therapeutics, Merger, Clinical Trials, Biopharmaceutical, Going Concern, TRX100, TRX01, Narazaciclib, Rigosertib, COVID-19, Influenza, Endometrial Cancer, Private Placement, Contingent Value Rights, Restructuring, Nasdaq